Category - Developments

Developments

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

Sio Gene Therapies (NASDAQ:SIOX) is presenting new biomarker data from the company’s study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

May 13, 2021

Developments

IntelGenx expands psychedelics accord with atai

IntelGenx (TSXV:IGX; OTCQB:IGXT) entered into a second feasibility agreement with atai Life Sciences AG for the development of novel formulations of Salvinorin A, a naturally occurring psychedelic compound being...

May 12, 2021

Developments

Clene presents positive Phase 2 interim ALS efficacy data

Clene (NASDAQ:CLNN) presented positive blinded interim efficacy data from its ongoing Phase 2 RESCUE-ALS clinical trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in the treatment...

May 12, 2021

Developments

RNA Disease Diagnostics inaugural board of directors and advisory board meet

Closely-held RNA Disease Diagnostics held an inaugural joint meeting of its board of directors and advisory board, which will work alongside the leadership team to advance the company’s...

May 11, 2021

Developments

IntelGenx shareholders approve atai Life Sciences investment

Shareholders at a virtual annual meeting of IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) approved atai Life Sciences AG’s investment in IntelGenx. Under the accord, atai initially will acquire an approximate 25%...

May 11, 2021

Developments

RNA Disease Diagnostics stepwise protocol for molecular diagnosis of COVID-19 published in Nature Protocols

RNA Disease Diagnostics’ stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test for COVID-19 was published in Nature Protocols. The test uses a unique dual-pronged molecular...

May 6, 2021

Developments

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) signed a multi-site imaging center agreement for its TULSA-PRO device with Akumin (NASDAQ, TSX:AKU), a leading provider of freestanding, fixed-site outpatient diagnostic imaging...

May 6, 2021

Developments

Hepion Pharma completes patient recruitment in Phase 2a AMBITION trial of CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) completed recruitment for its Phase 2a AMBITION clinical trial, with all non-alcoholic steatohepatitis (NASH) patients in the 225 mg CRV431 dosing cohort now enrolled. After...

May 6, 2021

Developments

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) SVP of clinical pharmacology and analytics, Dr. Patrick Mayo, gave a virtual presentation entitled, “CRV431 – From Benchtop to Bedside Clinical Development” at the 4th Global NASH...

April 29, 2021

Developments

Three finalists named for 2021 Bloom Burton Award

Daniel Durocher, Ph.D., scientific co-founder of Repare Therapeutics; Carl Hansen, Ph.D., founder and CEO of AbCellera; and Hamed Shahbazi, chairman and CEO of WELL Health Technologies are the three finalists for the...

April 27, 2021

Category - Developments

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

IntelGenx expands psychedelics accord with atai

Clene presents positive Phase 2 interim ALS efficacy data

RNA Disease Diagnostics inaugural board of directors and advisory board meet

IntelGenx shareholders approve atai Life Sciences investment

RNA Disease Diagnostics stepwise protocol for molecular diagnosis of COVID-19 published in Nature Protocols

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

Hepion Pharma completes patient recruitment in Phase 2a AMBITION trial of CRV431 in advanced NASH

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Three finalists named for 2021 Bloom Burton Award

General

More